The global preimplantation genetic testing market is valued at USD 493.24 Million in 2021 and expected to reach USD 873.14 Million by 2026 and forecasted to be growing at a CAGR of 12.1% between 2021 to 2026.
Preimplantation genetic detection is a method that examines the embryos that are created using the process of in vitro fertilization. This facilitates the implantation of only selected fit embryos into the uterus, ensuring that a healthy baby is delivered. This prevents the carrying of genetic disorders into the family generations. A screening process does the testing wherein the healthy ones are frozen and stored.
Due to the hectic, sedentary, and non-active modern life, many couples face difficulties conceiving naturally. The increasing pollution and chemicals in farming and animal husbandry sectors have greatly exacerbated infertility in the millennial generation. Some couples might also have genetic diseases that they might not wish to be passed down to their offspring. In these cases, embryos that have been fertilized in vitro have the option of being examined to see if they contain any harmful genetic matter or any disease that either of the parents has. This advancement in science has allowed many couples to have children who might have otherwise not tried at all.
The global preimplantation genetic testing market is primarily driven by the rise in infertility rate in individuals, lifestyle changes, PCOD syndrome in women, hereditary genetic disorders in the couple, advancements in genetics, therapies to resolve chromosomal anomalies, increase in fertilization treatment centers. These are the drivers that are propelling the growth of the preimplantation genetic testing market. Apart from all these, the scientific advancements in developing countries and lifestyle changes, especially in women's lives, are making them expose to hormonal changes. These aspects are propelling the market for further expansion.
There are plethoras of opportunities for the market to expand as the prevalence of infertility in almost all women and genetic disorders due to chemically processed food consumption. Due to this, there is a need for preimplantation genetic therapy, and it will reduce the exposure of genetic disorders and other defects in the embryo and helps in delivering a healthy baby. Hence, preimplantation genetic testing provides ample scope for pre-decided genetically modified babies. This is an opportunity of using preimplantation genetic testing. This triggers the market in a very optimistic way.
There are few restraints to the market in terms of technology and regulatory approvals. As the preimplantation genetic testing involves in vitro fertilization of embryo and unnatural conceiving of individual, there might be events of unregulated surrogacy in case of parents not opting for own bearing of the baby. The high cost of treatments and fertilization treatments are the other factors that restrain the market from growing. Lack of proper awareness among the people in rural and remote areas of developing and underdeveloped countries also inhibits the market from expanding further.
There are certain challenges for the market to expand. Further, they are cost-related factors, using non-invasive therapies, complicated genetic treatments like removing disease-causing RNA. So, as the process involves complicated treatments a robust and sophisticated treatment knowledge is necessary. Adverse effects of preimplantation therapies should be addressed effectively. These are some of the challenges that are faced while adopting such Embryo implantation therapies.
Impact of COVID-19 on the global preimplantation genetic testing market:
The pandemic has created great havoc on the economy in every aspect. The health care sector had burdened to a large extent, and the sector's potential is squeezed off. There is a huge supply chain and value chain disruption in the world. The pandemic has affected the livelihood and health of people. In this scenario, there is research finding that the fertility rate has increased. Still, when discussing the preimplantation market, many people who have the disorders are reluctant to visit the clinics and therapeutic centers due to stigma associated with the covid 19, and this has created a sluggish market growth in these times. But the other kind of preimplantation utilities like consumable and software services had witnessed a positive growth rate.
Market Size Available
2021 to 2026
2021 to 2026
By Procedure Type, Technology, Product and Service, Application, End-User and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
Illumina Inc., Yikon Genomics, CooperSurgical, Oxford Gene Technology, Inc., Thermo Fisher Scientific, Inc., Rubicon Genomics, Inc., Agilent Technologies, Inc., Natera, Inc., Abbott Laboratories, PerkinElmer, Inc., and SciGene Corporation.
This research report on the global preimplantation genetic testing market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2026.
Preimplantation Genetic Testing Market - By Procedure Type:
Preimplantation Genetic Testing Market - By Technology:
Of all these technological divisions, next-generation sequencing and fluorescent in situ hybridization lead the segment. This can be attributed to the requirements in sequencing the genomes of newborn babies and efficient fertilization in the case of in vitro fertilization.
Preimplantation Genetic Testing Market - By Product and Service:
Preimplantation Genetic Testing Market - By Application:
In these applications, HLA typing and chromosome anomalies are the ones that lead the market on a growth trajectory.
Preimplantation Genetic Testing Market - By End-users:
Based on the end-users, fertility clinics and maternity centers are the most lucrative areas of the market growth. This can be attributed to the in-clinic treatments and therapies involving preimplantation genetic testing procedures.
Preimplantation Genetic Testing Market - By Region:
Geographically, the top two regional markets for preimplantation genetic testing are North America and Europe. This can be attributed to the high average wage levels and minimal inequality in access to quality healthcare. Next to the US and Canada, the EU region is the second leading market; this can be attributed to the lifestyle changes and high infertility rates in the UK, Germany, and Spain in particular.
Despite being smaller than the top two markets, the market in the Asia Pacific is projected to increase with the highest rate during the forecast period. In the APAC region, China, India, and Japan are the leading markets; this can be attributed to the huge population and high fertility rates associated with the change in lifestyles, triggering the demand for the usage of preimplantation genetic testing methods.
In Latin America and middle east countries, Brazil, South Africa, and Saudi Arabia lead the market segment. This can be attributed to the increased health expenditure in these countries.
KEY MARKET PLAYERS:
Some of the promising companies operating in the global preimplantation genetic testing market profiled in the report are Illumina Inc., Yikon Genomics, CooperSurgical, Oxford Gene Technology, Inc., Thermo Fisher Scientific, Inc., Rubicon Genomics, Inc., Agilent Technologies, Inc., Natera, Inc., Abbott Laboratories, PerkinElmer, Inc. and SciGene Corporation.
Illumina Inc., one of the key market participants in the global preimplantation genetic testing market, was founded by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik and, Mark Chee in the year 1998. The company mainly develops, manufactures, and markets integrated systems to analyze genetic variation and testing. It was headed by Francis deSouza, who acted as its CEO and President. As of 2017, it had 5,500 employees and reported net revenue of USD 2.752 billion.
RECENT MARKET DEVELOPMENTS:
KEY HIGHLIGHTS OF THE REPORT:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Procedure Type
5.1.2 Preimplantation Genetic Screening
5.1.3 Preimplantation Genetic Diagnosis
5.1.4 Y-o-Y Growth Analysis, By Procedure Type
5.1.5 Market Attractiveness Analysis, By Procedure Type
5.1.6 Market Share Analysis, By Procedure Type
5.2.2 Next-Generation Sequencing
5.2.3 Polymerase Chain Reaction
5.2.4 Validation Biomarkers
5.2.5 Fluorescence in Situ Hybridization
5.2.6 Comparative Genomic Hybridization
5.2.7 Single-Nucleotide Polymorphism
5.2.8 Y-o-Y Growth Analysis, By Technology
5.2.9 Market Attractiveness Analysis, By Technology
5.2.10 Market Share Analysis, By Technology
5.3 Product and Service
5.3.2 Reagents and Consumables
5.3.4 Software and Services
5.3.5 Y-o-Y Growth Analysis, By Product and Service
5.3.6 Market Attractiveness Analysis, By Product and Service
5.3.7 Market Share Analysis, By Product and Service
5.4.3 Structural Chromosomal Abnormalities
5.4.4 Single Gene Disorders
5.4.5 X-Linked Disorders
5.4.6 HLA Typing
5.4.7 Gender Identification
5.4.8 Y-o-Y Growth Analysis, By Application
5.4.9 Market Attractiveness Analysis, By Application
5.4.10 Market Share Analysis, By Application
5.5 End users
5.5.2 Maternity Centers & Fertility Clinics
5.5.3 Hospitals, Diagnostic Labs, and Service Providers
5.5.4 Research Laboratories & Academic Institutes
5.5.5 Y-o-Y Growth Analysis, By End-users
5.5.6 Market Attractiveness Analysis, By End-users
5.5.7 Market Share Analysis, By End-users
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Procedure type
184.108.40.206 By Technology
220.127.116.11 By Product and Service
18.104.22.168 By Application
22.214.171.124 By End user
6.1.4 Market Attractiveness Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Procedure type
184.108.40.206 By Technology
220.127.116.11 By Product and Service
18.104.22.168 By Application
22.214.171.124 By End-user
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Procedure type
184.108.40.206 By Technology
220.127.116.11 By Product and Service
18.104.22.168 By Application
22.214.171.124 By End-user
6.2 North America
6.2.2 United States
6.4.6 South Korea
6.5 Latin America
6.5.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Illumina, Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fisher Scientific Inc.
8.3 Agilent Technologies, Inc.
8.4 Perkinelmer, Inc.
8.5 Coopersurgical, Inc.
8.6 ABBott Laboratories
8.7 Natera, Inc.
8.8 Rubicon Genomics, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures